Vitasora Health (VHL) Status Update summary

Operational milestones and financial performance

• Achieved record recurring revenue of $200,000 for the quarter and a record month in June at nearly $100,000, with client numbers increasing from 13 to 25 and patient numbers rising to 1,500, a 353% surge.

• Rationalized client base to focus on profitable, scalable clients, removing legacy and unprofitable accounts.

• July patient numbers were already 20% higher than June, with a strong pipeline and no need for new clients to reach cash flow positivity by year-end.

• Conversion rate for onboarding high-risk patients is approximately 70%, with 40,000 high-risk patients available from current clients.

• Clinic in Cloud services exceeded expectations, reaching $190 per patient per month for some programs, well above the $130 target.

Strategic direction and growth outlook

• Confident in achieving monthly cash flow positivity by end of 2024, requiring 7,500 patients (down from 9,000) due to improved efficiency and higher per-patient revenue.

• Pipeline includes over 500,000 high-risk lives for future onboarding, with significant opportunities in risk-share and capitated models.

• Focus shifting from small clients to larger organizations such as ACOs, IPAs, insurers, and MSOs for scalable growth.

• M&A remains a priority, supported by a $20 million fund for strategic acquisitions that are EPS accretive and offer cross-selling opportunities.

• No immediate plans for a US listing, but options are being evaluated to maximize shareholder value.

Differentiation and service innovation

• Offers a broad portfolio of remote patient services, including remote patient monitoring, chronic care management, and AI-powered predictive analytics.

• Unique wheezo device and Clinic in Cloud platform drive client engagement and open new business opportunities, especially in COPD care.

• Flexible revenue models include fee-for-service, Clinic in Cloud, and risk-share contracts, aligning with evolving US healthcare reimbursement trends.

• Risk-share contracts provide predictable, immediate revenue and upside from shared savings, with current negotiations involving major ACOs and insurers.

• Clinical outcomes, such as significant improvements in Asthma Control Test scores, underpin value proposition and client trust.